PF-Atlas › Clinical Trials › NCT04030026

A Study of Nalbuphine ER in Idiopathic Pulmonary Fibrosis for Treatment of Cough

NAL ER · Phase 2

Registry ID
NCT04030026
Phase
Phase 2
Status
Completed
Drug / intervention
NAL ER
Sponsor
Trevi Therapeutics
Start
2019-10-29
Enrollment
42
Locations
11

About this trial

To evaluate the safety and tolerability of nalbuphine ER tablets in the study population and to evaluate the effect of NAL ER tablets on the mean daytime cough frequency (coughs per hour) at Day 22 (dose 162 mg BID) as compared to placebo tablets.

View NCT04030026 on ClinicalTrials.gov →

Explore related

All NAL ER trialsAll IPF trials

Related trials

NAL ER — NCT05964335NAL ER — NCT07671911NAL ER — NCT07036029
Medical disclaimer. This page summarizes public trial data for NCT04030026 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.